Skip to main content

Welcome to a Grasp lesson

Create a free account to keep studying and create your own study path.

Lesson 7

Licensed and Investigational Monoclonal Antibody Treatments for Ebola Viruses

Recommended resources

Hello. In the previous lesson, you saw how fluids, electrolyte correction, and close monitoring can help a patient survive the effects of Ebola disease. That care matters regardless of which virus caused the illness. This lesson adds a different kind of treatment: monoclonal antibodies, medicines directed at the virus itself. The distinction is that the licensed antibodies are for infection caused by Ebola virus—often called Zaire Ebola virus—not automatically for disease caused by Sudan or Bundibugyo virus.


What an antibody treatment is meant to do

An antibody is a protein that can recognize and attach to a particular target, or antigen. A monoclonal antibody medicine supplies antibodies made to recognize a chosen viral target. Ebola viruses carry proteins on their surface that help them enter human cells. An antibody that binds an appropriate part of such a protein can interfere with infection.

Stylized blue antibodies attach to red antigen shapes. The image illustrates binding, not an Ebola virus particle or evidence that one antibody binds every virus that causes Ebola disease.

That last distinction matters. Recognizing a target on Ebola virus does not establish that the same medicine will work against Sudan virus or Bundibugyo virus. Related viruses can have differences in the surface proteins an antibody must recognize. Scientists have to test whether a proposed treatment works against each virus; a shared disease name is not enough.

Antibodies and supportive care address different problems. An antibody treatment aims to act against the virus. Fluids, electrolyte correction, and other supportive measures address the damage and complications of illness. Receiving an antibody does not make hydration or monitoring unnecessary.



Which treatments are licensed for Ebola virus infection?

Read the FDA’s terminology note and therapeutics section. The note explains why a report saying only “Ebola” may not identify the virus precisely enough to interpret a treatment claim.

Ebola | FDA

The US Food and Drug Administration (FDA) identifies two approved monoclonal-antibody treatments and specifies the infection each is approved to treat.

Under Medical countermeasures, read the terminology note beginning “The term Ebola virus was for years used to describe” through the paragraph ending “same countermeasures.” Read the distinction between Ebola virus and other viruses in the group. Then, under Therapeutics, read the Ebanga paragraph from “On December 21, 2020, the FDA” through “preventing its entry into the cell.” Read about Ebanga. Read the start of the next paragraph, from “On October 14, 2020, the FDA announced” through “in adult and pediatric patients.” Read about Inmazeb. Focus on the virus named in each approval, rather than the detailed lists of possible reactions.

The two names to retain are Ebanga and Inmazeb. Ebanga contains one monoclonal antibody, ansuvimab, also called mAb114. Inmazeb contains a mixture of three monoclonal antibodies, also called REGN-EB3. Both have FDA approval for treating infection caused by Ebola virus in adults and children. They are treatments for infection, not general-purpose medicines against every virus associated with Ebola disease.

You may encounter different terminology in outbreak reports. “Zaire” is a historical identifier often used to distinguish Ebola virus from Sudan virus and Bundibugyo virus. Taxonomic group names also vary between older and newer sources. For this lesson, the practical point is to find the specific virus named in the report before deciding whether a treatment claim applies.



What changes when the virus is Sudan or Bundibugyo?

The World Health Organization (WHO) gives a useful comparison: it recommends the two monoclonal-antibody treatments for Ebola virus disease, while stating that there are no approved therapeutics for Sudan virus disease or Bundibugyo virus disease. “No approved therapeutics” does not mean “no care.” Patients can still receive the supportive treatment you studied previously.

Ebola disease

The World Health Organization (WHO) places the approved treatments alongside supportive care and explains the current status of treatments for disease caused by other Ebola-related viruses.

In Overview, read from “Ebola disease is caused by viruses that belong to the” through “Candidate products are in development.” Read the overview, noting the difference between viruses that cause outbreaks. Then go to Treatment and read from “Over the years, WHO and partners have developed” through “for clinical trials is available.” Read the treatment section. Notice that optimized supportive care is described separately from the two recommended antibodies and from products still in development.

A candidate treatment is being investigated; it is not the same as an approved treatment with established clinical use for that infection. Researchers may study a candidate in carefully governed trials, but promising laboratory or animal results alone do not demonstrate that it improves survival in people. Nor does FDA approval for Ebola virus infection establish an approved use for Sudan or Bundibugyo virus disease.

This short research video makes the scientific problem visible. It is an older account of an experimental antibody, not a current guide to approved medicines. Use the FDA and WHO readings—not the video’s historical statements about what was available at the time—for the present treatment distinction.

Science Talk: Antibody Neutralizes Two Deadliest Ebola Virus Species

In “Science Talk: Antibody Neutralizes Two Deadliest Ebola Virus Species,” Albert Einstein College of Medicine describes research on an antibody designed to recognize more than one Ebola-related virus. Watch for the difference between designing a promising antibody and establishing a treatment for patients.

Watch antibody design for how differences in viral surface proteins motivate the proposed dual-targeting antibody. Then watch animal testing, especially the explanation that results in mice are an early step rather than confirmation of human effectiveness. Statements in this older video about the number of available treatments should not be taken as current.

The treatment landscape can therefore be stated without either overstating or dismissing research:

Virus causing disease Virus-specific treatment status Care that remains important
Ebola virus (often called Zaire) Ebanga and Inmazeb are approved monoclonal-antibody treatments for this infection. Optimized supportive care
Sudan virus No approved virus-specific therapeutic; candidates are under development. Optimized supportive care
Bundibugyo virus No approved virus-specific therapeutic; candidates are under development. Optimized supportive care

Suppose a news report says that an outbreak is caused by Sudan virus and then mentions “approved Ebola antibody drugs.” Both statements might be individually recognizable, but the implied treatment conclusion does not follow. The approved antibodies named here are for Ebola virus infection. A report would need separate evidence to support a claim that a treatment works against Sudan virus, and it should distinguish an investigational candidate from an approved medicine.



Key takeaways

Ebanga (mAb114/ansuvimab) and Inmazeb (REGN-EB3) are monoclonal-antibody treatments approved for Ebola virus infection. Their role is different from supportive care, which remains essential. For disease caused by Sudan or Bundibugyo virus, there is no approved virus-specific therapeutic in the WHO account; treatments under investigation must not be presented as licensed or proven for patients.

The next module moves from treating an individual patient to breaking chains of transmission, beginning with how contact tracing identifies people who need monitoring after an exposure.